gastric juice raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
In the 1970s, biscuit manufacturers began using micro-aeration to process chocolate for moulded products. This was a cost-saving measure: with less chocolate, the same volume of coated biscuit could be maintained. In 1981 or 1983, Cadbury released Wispa, an aerated chocolate with a more chunky shape than Aero bars, made using a secret, non-patented process. The launch of Wispa was successful, but it soon encountered manufacturing difficulties and was temporarily withdrawn from the market. While Wispa was off the market, Rowntree's developed and launched a chunky Aero which they successfully launched and was still being sold as of 2008. Wispa was discontinued in the early 2000s so Cadbury could bring in a new aerated chocolate product aligned with the Cadbury Dairy Milk brand: Dairy Milk Bubbly. Following an internet campaign in 2007, Cadbury reintroduced Wispa. Today, Aero is manufactured by Nestlé, the brand having been acquired by Nestlé during a 1988 takeover of Rowntree's. As of 2023, other brands of aerated chocolate includes Mirage and Galaxy.
Models of well-being are frameworks for understanding and measuring well-being. They clarify its nature and seek to show how its different components and contributing factors interact. Psychologist Ed Diener's tripartite model identifies three essential components of subjective well-being: the presence of positive affect, the absence of negative affect, and a positive evaluation of one's life as a whole. Psychologist Carol Ryff proposed the six-factor model of psychological well-being. It states that the main elements are self-acceptance, personal growth, purpose in life, environmental mastery, autonomy, and positive relations with others. Focusing on social well-being, sociologist Corey Keyes developed a five-component model based on social integration, social contribution, social coherence, social actualization, and social acceptance. According to Martin Seligman's PERMA theory, well-being has five elements: positive emotions, engagement by following one's interests, interpersonal relationships, finding meaning in life, and accomplishments in the pursuit of success and mastery. Psychologist Michael Bishop developed the network model of well-being, which includes components such as feelings, emotions, attitudes, traits, and interactions with one's environment. This model emphasizes that the different components form a causal network by influencing and reinforcing each other in complex ways.
=== Contestants === 1st - Renee Loranger, Pastry Chef from Waveland, Mississippi 2nd - Guillermo Salinas from Jackson, Mississippi 2nd - Adina Schaefer, Executive Pastry Chef from Los Angeles, California 4th - Megan Baker, Bakery Owner from Minneapolis, Minnesota 5th - Ashley Wong from Fremont, California 6th - Wes Dills from Austin, Texas 7th - Sherelle Morrison from Indian Land, South Carolina 8th - Jocelyn Jung, Bakery Owner from San Diego, California 9th - Anirudh Mamtora from Cherry Hill, New Jersey 9th - Nicole Proske from Miami, Florida 11th - Steven Sechoka from Boston, Massachusetts 12th - Paul Allicock from Miami, Florida
Sources: en.wikipedia.org
Bragg was influential in the effort to beat a leading American chemist, Linus Pauling, to the discovery of DNA's structure (after having been pipped at the post by Pauling's success in determining the alpha helix structure of proteins). At the same time Bragg's Cavendish Laboratory was also effectively competing with King's College London, whose Biophysics department was under the direction of Randall (Randall had refused Crick's application to work at King's College). Francis Crick and Maurice Wilkins of King's College were personal friends, which influenced subsequent scientific events as much as the close friendship between Crick and James Watson. Crick and Wilkins first met at King's College and not, as erroneously recorded by two authors, at the Admiralty during World War II. In 1995 Francis Crick signed the Ashley Montagu Resolution petitioning the International Court of Justice (previously the World Court) to help end genital mutation of children, including female genital mutilation, circumcision, and penile subincision.
== Cellular distribution == Since 5-HEDH has not been defined biochemically or genetically, studies on its distribution have been limited to examining the ability of cells or cell microsomes to make 5-oxo-ETE from 5(S)-HETE. A wide variety of cell types possess this activity including blood neutrophils, monocytes, eosinophils, B lymphocytes, and platelets; airway epithelial cells, airway smooth muscle cells, vascular endothelial cells, and monocytes differentiated in vitro to dendritic cells; and cancer cell lines derived from many of these cells or from prostate, breast, and colon cancer cells.
== History == Sean Vanaman and Jake Rodkin were both at Telltale Games as co-writers on the 2012 game The Walking Dead, which was considered Telltale's first turn into a more narrative type of episodic adventure game. The game was a critical success, and while other projects came along, Vanaman started to become too comfortable with his role at Telltale, and felt that he would be more motivated if there was more discomfort or risk in his duties. After talking about the idea with Rodkin, the two left the company and co-founded Campo Santo on September 18, 2013, joined by Mark of the Ninja designer Nels Anderson and graphic artist Olly Moss. Environment artist Jane Ng and designer and composer Chris Remo, who had also worked with Vanaman and Rodkin on the Idle Thumbs podcast, soon joined the team as well. Soon after, they announced Panic would back their debut project. After a painting by Moss, Ng adapted the painting's aesthetic style into a 3D environment with the color and inspiration drawn from both New Deal advertisements and icons from the National Park Service as well as a camping trip in Yellowstone National Park in which the team visited a preserved fire lookout tower two miles (3.2 km) from the campsite. Development eventually led to the announcement of Firewatch in March 2014, with release originally slated for 2015. In August 2014, a game demo of Firewatch was released at PAX West, revealing the overall plotline and story of a fire lookout named Henry in the Shoshone National Forest in 1989.
A 2023 study also found evidence that Neanderthal single nucleotide polymorphisms (SNPs) likely play a "significant role" in autism susceptibility and heritability in autism populations across the United States. According to the study, "Although most studies on autism genomics focus on the deleterious nature of variants, there is the possibility some of these autism-associated Neanderthal SNPs have been under weak positive selection. In support, recent studies have identified genetic variants implicated in both autism and high intelligence. Meanwhile, autistic people often perform better on tests of fluid intelligence than neurotypicals." Another 2017 study that analyzed 68 genes associated with neurodevelopmental disorders, including autism, found that these disorders were also affected by natural selection and interbreeding between Homo sapiens and other archaic human species. The study also recommended further research into the link between Neanderthal single nucleotide polymorphisms (SNPs) and neurodevelopmental disorders, including autism, in modern-day humans.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.